Independent newsroom

Thursday, November 19, 2026

The File

Every claim traces to a primary source. Uncertainty is labeled. Corrections are public.

Health · Thursday, November 19, 2026

FDA approves first drug for the brain symptoms of Type 3 Gaucher

The File desk · Nov. 19, 2026, 6:24 a.m. ET

Confirmed1 primary sourcesAdded 6:24 a.m. ET, Nov. 19

Status

Confirmed. The approval, the trial description, the side effects, and the commissioner's quote are in the FDA's news release of November 18, 2026. The trial results are as the FDA describes them. The release states no price and no launch date.
  • Confirmed
    The FDA approved Infilbray (venglustat) tablets as the first treatment for the neurological symptoms of Type 3 Gaucher disease in patients weighing at least 15 kg.
  • Confirmed
    The supporting study enrolled 43 patients aged 12 and older, comparing a daily tablet with intravenous enzyme replacement for 52 weeks.
Type 3 Gaucher disease does its damage in the brain, behind a filter that keeps many substances in the blood from getting in. The Food and Drug Administration has approved a tablet for that form of the disease.1 On Wednesday, November 18, 2026, the agency said Infilbray (venglustat) is "the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds)."1
How does a tablet reach trouble on the far side of that filter? The filter is the blood-brain barrier, and the FDA says Infilbray "crosses the blood-brain barrier."1 That matters because a drug that stays in the bloodstream cannot reach symptoms that sit in the brain.
The disease itself is a failure of breakdown. GD3 "is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids."1 Unlike type 1, GD3 affects the brain and nervous system, including balance, coordination, speech, memory, and thinking.1 Infilbray works as a "glucosylceramide synthase inhibitor," which means it slows the step that makes more of the fatty substance the body cannot clear.1
Acting FDA Commissioner Kyle Diamantas, J.D., joined the two ideas in one sentence: "For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms."1
Now notice how the evidence was built. The study was randomized and double-blind, and every one of its 43 patients was already stable on enzyme replacement therapy.1 In this release, enzyme replacement is the intravenous treatment for the disease's effects outside the brain. For 52 weeks, patients either took Infilbray once daily by mouth or stayed on that intravenous treatment.1 At Week 52, the tablet group improved on a combined measure of ataxia and cognitive function compared with enzyme replacement.1 Ataxia, the release says, is loss of muscle control and coordination.
The drug carries risks. The most frequently reported side effects include gastrointestinal symptoms and adverse effects on mood.1 The release states the most serious plainly: "Serious psychiatric risks, including suicidal ideation and behavior, have been reported."1 It also cites animal-study risks: possible clouding of vision in younger patients, and adverse effects on fetal development when the drug is taken during pregnancy.1
Infilbray came through the agency with two labels attached. It received Orphan Drug designation, a status the FDA uses for drugs aimed at rare diseases, and Priority Review, a faster review track.1 The release does not spell out the statutes behind either one. Approval was granted to Genzyme Corporation, a Sanofi Company.1
Why it matters (Estimate). Estimate. Families dealing with Type 3 Gaucher disease have had an intravenous treatment for the disease outside the brain and, until this approval, no drug the FDA calls a treatment for the neurological symptoms. The next facts a patient would want are a price and a date the tablets are available, and neither is in the release. This is our reading of the FDA's announcement.
A tablet once a day, for symptoms that sit behind the blood-brain barrier. And that is where things stand.
How we know

Notes

  1. 1.Food and Drug Administration, "FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease," For Immediate Release, November 18, 2026. The agency "today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds)." It "crosses the blood-brain barrier." GD3 "is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids." Unlike type 1, it affects the brain and nervous system, including balance, coordination, speech, memory, and thinking. Mechanism: "glucosylceramide synthase inhibitor." Study: randomized, double-blind, multicenter, 43 patients aged 12 and older previously stabilized on enzyme replacement therapy; once-daily oral Infilbray versus intravenous enzyme replacement every two weeks for 52 weeks; at Week 52, improvement on a combined measure of ataxia and cognitive function versus enzyme replacement for non-neurologic manifestations. Side effects: gastrointestinal symptoms, adverse effects on mood. "Serious psychiatric risks, including suicidal ideation and behavior, have been reported." Animal-study risks include potential clouding of vision in younger patients and adverse effects on fetal development. Orphan Drug designation and Priority Review. Approval granted to Genzyme Corporation, a Sanofi Company. Quote from Acting FDA Commissioner Kyle Diamantas, J.D., as in the story, and a second sentence: "This approval reflects the FDA's commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them." Retrieved by The File desk, Nov. 19. Confirmed. Source 1. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease

What is still unknown or disputed

  • How common Type 3 Gaucher disease is. The release does not give a prevalence number, and this story does not add one.
  • The price and the launch date. The release does not state them.
  • Results beyond what the FDA summarizes. This desk did not open a separate trial registry.

Primary sources

Every claim in this story is drawn from the documents below. If a fetch failed, that is recorded on the card.

  1. Source 1

    FDA approves Infilbray for Type 3 Gaucher disease

    U.S. Food and Drug Administration · November 18, 2026

    The FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease in patients weighing at least 15 kg.

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease